SureTrader SPDR Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus Bioscience Holdings Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, JJAAMMAANN, Rosym
Search This Board:
Last Post: 9/3/2015 4:22:05 AM - Followers: 724 - Board type: Free - Posts Today: 3

 

(AMBS) Amarantus BioScience Holdings, Inc. 

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.

The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") is a
 diagnostic blood test for Alzheimer’s disease and is being evaluated as a diagnostic blood test for Traumatic Brain injury and Chronic Traumatic Encephalopathy.  (MANF) is a human growth factor that plays a key role in the prevention of apoptosis (cell death). It is being developed for the potential treatment of RP, Parkinson's disease, Wolfram syndrome, diabetes, Alzheimer's disease and traumatic brain injury.
Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
For further information, please visit www.Amarantus.com, or connect with the company in FacebookTwitter, LinkedIn & Google+

 
 
    

 


 
PRESS RELEASES & NEWS ARTICLES
AUGUST 05, 2015
Amarantus Announces Adjournment of Annual Meeting  -  The annual meeting has been adjourned to August 7, 2015 at 10:00 a.m. EDT at Sichenzia Ross Friedman Ference LLP, 61 Broadway, 32nd Floor, New York, New York 10006
Aug. 3, 2015
Amarantus BioScience, U.S. Army and Rutgers University in Partnership to Expand Development of Engineered Skin Substitute (ESS) for the Treatment of Severe Thermal Burn Wounds - 
"This CRADA represents an important partnership for Amarantus as we work with the USAISR and Rutgers to advance the clinical program for ESS," said Gerald E. Commissiong, President & CEO of Amarantus.
AUGUST 03, 2015
Amarantus Diagnostics logo   Amarantus Announces Publication of a Clinical Study of MSPrecise(R) Diagnostic for Identification of Relapsing-Remitting Multiple Sclerosis (RRMS) in the Journal GENE
JULY 29, 2015
Amarantus BioScience Initiation of coverage Building up therapeutics assets
July 27, 2015
Amarantus Diagnostics Establishes Strategic Advisory Committee - Advisors Bring Over 30 Years of Expertise in Successfully Commercializing Molecular Diagnostics Companies
July 27, 2015 
SeeThruEquity Initiates Coverage on Amarantus BioScience Holdings, Inc. with a Price Target of $45.34
JULY 24, 2015
Amarantus Diagnostics Meets Primary and Secondary Endpoints in Blinded, Multi-Center LP-002 Clinical Study for LymPro(R) Blood Diagnostic for Alzheimer's Disease and Confirms LymPro's Fit-For-Purpose Use in Clinical Trials at the 2015 Alzheimer's Association International Conference(R)
July 22, 2015
Amarantus Announces First Patient Dosed in Eltoprazine Phase 2b Study for Treatment of Parkinson's Disease Levodopa-Induced Dyskinesia
JULY 20, 2015

More News
 
 
 

 Gerald E. Commissiong on LymPro 
Published on Jul 24, 2015

Predicting Alzheimer's before it starts
 Published on Apr. 8, 2015
                                                                                                                  
 

Developing an Accurate Test for Multiple Sclerosis
Mar. 5, 2014
 

SNNLive - Amarantus BioScience Holdings, Inc
Dec. 12, 2014

 

Amarantus BioScience
Oct. 19, 2014


 

 

 
    
       
 


Company Information

Amarantus BioScience Holdings, Inc.
655 Montgomery Street
Suite 900
San Francisco, CA 94111

 

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland












 

info@amarantus.com
pr@amarantus.com


Phone: (415) 688-4484
Fax: (408) 852-4427


Gerald's email address
Gerald@amarantus.com



IR Calendar 
 







 

INVESTOR RELATIONS

Jenene Thomas Communications
Jenene Thomas
T: 908-938-1475

ir@amarantus.com


 

TRANSFER AGENT

VStock Transfer, LLC
Allison Niccols
77 Spruce Street
Suite 201
Cedarhurst, N 11516
T: 212-828-8436
F: 646-536-3179
info@vstocktransfer.com
www.VStockTransfer.com

 

 
Throughout my 50+ years in the biopharmaceutical industry, I have seen many programs with great promise, but very few programs that possess the fundamentally groundbreaking scientific potential to modify disease biology inherent in MANF This vast potential for MANF is what makes today’s announcement personally so exciting for me, as the initiation of IND-enabling studies (which start with initiation of clinical grade manufacturing) has been the rate-limiting step for true product development value creation for MANF not only for the ophthalmology programs, but also the rest of the MANF pipeline.

 
  Dr. Wen commented, "We continue to see very encouraging preclinical data with MANF. I am looking forward to continue further development of MANF in collaboration with Amarantus, as I believe it has the potential to address RP, as well as other ophthalmologic disorders with serious unmet need and improve the quality of life of patients where no viable treatments exist today."
More information
         “We are very pleased with the data generated in RP from Dr. Wen’s lab at University of Miami’s Bascom Palmer Eye Institute, one of the world’s most prestigious ophthalmology research and treatment centers,” said Gerald E. Commissiong, President & CEO of Amarantus BioScience Holdings, Inc. “Given the recent granting of orphan drug designations in both the US and EU, the presentation of this data is very timely as we build momentum for MANF in this devastating orphan indication, as well as continue to further establish the MANF orphan ophthalmology franchise.

   Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.
 

                                                                                            
        
                           2 Conferences

Sichenzia Ross Friedman Ference LLP  -  The annual meeting has been adjourned to September 2, 2015 at 10:00 a.m. EDT at , 
61 Broadway, 32nd
Floor, New York, New York 10006

First MANF & CDNF Proteins Symposium - Two-Day International Symposium, San Francisco, CA  -  September 14 -15, 2015 

                                                             



 
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/26/2015 02:36:12 PM
AMBS News: Additional Proxy Soliciting Materials (definitive) (defa14a) 08/26/2015 02:33:37 PM
AMBS News: Amarantus Moves Annual Meeting Date Forward to September 2, 2015 08/26/2015 12:30:00 PM
AMBS News: Current Report Filing (8-k) 08/20/2015 09:35:46 AM
AMBS News: Amarantus Announces Issuance of United States Patent Covering Proprietary Compositions of Matter and Methods of Use for Produ... 08/20/2015 08:35:00 AM
PostSubject
#116737  Sticky Note Jason Napodano, CFA ?@JNapodano 12h12 hours ago Rosym 08/04/15 08:53:08 AM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#117423   Which three are these? ESS, MSPrecise and ??? Eltoprazine? joboggi 09/03/15 04:22:05 AM
#117422   Can we expect a press release about yesterdays meeting? sante1 09/03/15 01:39:17 AM
#117421   F16 filing sante1 09/03/15 12:54:18 AM
#117420   Market Cap (intraday) $16.48-Mil. JPetroInc 09/02/15 07:16:51 PM
#117419   So, they had no news. I guess no joboggi 09/02/15 05:36:44 PM
#117418   Hopefully that was just a dilution dump. GOducks123 09/02/15 04:04:52 PM
#117417   Soooooooo. Is the up list not happening??? Ultimaratioregum 09/02/15 03:39:52 PM
#117416   AMBS Down 93% YTD. Stay away from Sgt. Pepper 09/02/15 01:10:37 PM
#117415   LOL! Pennies COMING AGAIN! SCAM! Sgt. Pepper 09/02/15 01:10:22 PM
#117414   TOXIC Financier DOMINION adds nearly 5% to ownership. Sgt. Pepper 09/02/15 01:10:11 PM
#117413   Warning! 150-1 Reverse Split in play. Shares Sgt. Pepper 09/02/15 01:09:58 PM
#117412   I don't think we have two weeks. GoClippers 09/02/15 11:43:32 AM
#117411   pay to play der_deutschetrader 09/02/15 11:42:41 AM
#117410   does that report provide future financing direction - JPetroInc 09/02/15 11:34:10 AM
#117409   See report on $AMBS here http://scr.zacks.com/News/Press-Releases/Press-Release zoomboom 09/02/15 11:08:55 AM
#117408   I would love to know what are those hobbystock 09/02/15 11:01:37 AM
#117407   @ZacksSmallCap Buy rating for Amarantus shares and adjust zoomboom 09/02/15 10:50:50 AM
#117406   only news you will get is that everything SidVicious 09/02/15 10:27:41 AM
#117405   so waiting for some news ron51 09/02/15 10:24:50 AM
#117404   10am EST. it might already be over hnbadger1 09/02/15 10:23:31 AM
#117403   thx ron51 09/02/15 10:23:16 AM
#117402   Started at 10 brharris 09/02/15 10:22:25 AM
#117401   Might not be anything to leak. I expect brharris 09/02/15 10:22:04 AM
#117400   At what time is the SHM? ron51 09/02/15 10:18:41 AM
#117399   Given that less than 1k shares have traded Ragnaroc 09/02/15 10:16:52 AM
#117398   Looks like people are waiting for news.How long Telcantor 1 09/02/15 10:02:14 AM
#117397   Whatever you say Sid. Won't be long before brharris 09/02/15 09:53:40 AM
#117396   Down -3% got -97% left to go, should LORD of the TITANS 09/02/15 09:52:14 AM
#117395   You think? Lol! For two years people kept SidVicious 09/02/15 09:47:43 AM
#117394   YEA YOU JUST HAVE TO SHAKE YOURE HEAD AT 27times 09/02/15 09:44:47 AM
#117393   LOL exactly!!! Sometimes I just shake my head brharris 09/02/15 09:40:58 AM
#117392   POS STOCK SCAM BY GERRY 27times 09/02/15 09:36:43 AM
#117391   Lol. This is great news, cause we are youngncurious 09/02/15 09:33:09 AM
#117390   BYE BYE AMBS 27times 09/02/15 09:28:47 AM
#117389   I think the plan will soon be playing brharris 09/02/15 09:13:57 AM
#117388   Note! My experience with these kind of transfers sante1 09/02/15 03:22:53 AM
#117387   brharris and that's just the point, that's the sante1 09/02/15 12:49:15 AM
#117386   Well said. That Sums it up perfectly :) GOducks123 09/01/15 10:56:21 PM
#117385   No worries GOducks, I understand what you are brharris 09/01/15 10:35:17 PM
#117384   Agreed. Sorry if I was a little rude GOducks123 09/01/15 10:16:08 PM
#117383   I have been here for 2 years and brharris 09/01/15 10:05:58 PM
#117382   Yes, that is true for most biotechs, but GOducks123 09/01/15 09:56:01 PM
#117381   Right, but in order to achieve that AMBS brharris 09/01/15 09:07:45 PM
#117380   The only one that will matter is funds BBalls-N-CowTown 09/01/15 09:00:05 PM
#117379   It does appear to be building a base brharris 09/01/15 08:51:48 PM
#117378   Someone (Sumotrader?) posted a good lead on a BBalls-N-CowTown 09/01/15 08:05:02 PM
#117377   I'm in hopes the share price is beginning JPetroInc 09/01/15 07:20:17 PM
#117376   When one talks of a RS with only brharris 09/01/15 05:01:32 PM
#117372   not following el_lobodewallst 09/01/15 04:04:14 PM
#117369   CDEL and CANT are loaded right behind as well JPetroInc 09/01/15 03:49:02 PM
PostSubject